Elevation Point Wealth Partners LLC Takes $496,000 Position in Waters Corporation $WAT

Elevation Point Wealth Partners LLC bought a new position in Waters Corporation (NYSE:WAT) during the 1st quarter, HoldingsChannel reports. The fund bought 1,665 shares of the medical instruments supplier’s stock, valued at approximately $496,000.

A number of other large investors have also recently modified their holdings of the stock. Zions Bancorporation National Association UT grew its stake in Waters by 121.2% in the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 40 shares during the period. Louisbourg Investments Inc. bought a new stake in shares of Waters in the 1st quarter worth $30,000. First United Bank & Trust purchased a new position in Waters in the 1st quarter worth about $31,000. North Star Investment Management Corp. lifted its position in Waters by 10,200.0% during the first quarter. North Star Investment Management Corp. now owns 103 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 102 shares during the period. Finally, SHP Wealth Management purchased a new position in shares of Waters in the 4th quarter worth $32,000. Institutional investors own 94.01% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on WAT. JPMorgan Chase & Co. boosted their target price on shares of Waters from $330.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, May 6th. Wells Fargo & Company boosted their price objective on shares of Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Wolfe Research assumed coverage on Waters in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 target price on the stock. Guggenheim reiterated a “buy” rating and set a $440.00 target price on shares of Waters in a research report on Wednesday. Finally, Royal Bank Of Canada initiated coverage on Waters in a report on Wednesday. They set an “outperform” rating and a $435.00 price target for the company. Four equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Waters currently has a consensus rating of “Moderate Buy” and an average target price of $401.60.

Waters Price Performance

Shares of Waters stock opened at $369.45 on Thursday. The company has a market capitalization of $36.28 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 2.27 and a beta of 1.20. The company has a quick ratio of 1.13, a current ratio of 1.79 and a debt-to-equity ratio of 0.32. The stock’s 50-day simple moving average is $355.56 and its 200-day simple moving average is $346.70. Waters Corporation has a 52 week low of $275.05 and a 52 week high of $414.15.

Waters (NYSE:WAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.39. The firm had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a return on equity of 15.60% and a net margin of 11.91%.The firm’s revenue was up 91.4% on a year-over-year basis. During the same quarter last year, the business posted $2.25 earnings per share. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, analysts expect that Waters Corporation will post 14.51 earnings per share for the current fiscal year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.